TD Cowen Upgrades IQVIA (IQV) to Buy and Raises Price Target to $213

IQVIA Holdings Inc. (NYSE:IQV) is one of the 10 Best Diagnostics and Research Stocks to Buy According to Analysts.

TD Cowen Upgrades IQVIA (IQV) to Buy and Raises Price Target to $213

On March 9, 2026, TD Cowen upgraded its rating on IQVIA Holdings Inc. (NYSE:IQV) from Hold to Buy. Along with the rating upgrade, the firm also raised its price target on the stock from $174 to $213. The company is anticipated to remain resilient against AI-driven revenue headwinds, according to TD Cowen analysts. It further noted that AI could potentially reduce drug trial costs by 10% to 15%, but these savings are expected to be further reinvested into research activity. Following a 24% share price decline since February, TD Cowen sees an attractive risk-reward opportunity.

Prior to this, in an unrelated event, Barclays also upgraded IQVIA Holdings Inc. (NYSE:IQV)’s rating from Equal Weight to Overweight, while maintaining a price target of $210. The firm’s analyst anticipates an upside for the stock, projecting higher valuations and financial estimates. It added in a research note that the consistency in its execution justifies a premium market valuation for IQVIA Holdings Inc. (NYSE:IQV).

Founded in 1982, IQVIA Holdings Inc. (NYSE:IQV) is a global leader in clinical research and health data, headquartered in North Carolina.

READ NEXT: 10 Best Stocks to Invest in During a Recession and 10 Best Space Exploration Stocks to Buy According to Analysts

Disclosure: None.  Follow Insider Monkey on Google News.